Compounds > orantinib
Page last updated: 2024-09-05

orantinib and entrectinib

orantinib has been researched along with entrectinib in 2 studies

Compound Research Comparison

Studies
(orantinib)		Trials
(orantinib)		Recent Studies (post-2010)
(orantinib)		Studies
(entrectinib)		Trials
(entrectinib)		Recent Studies (post-2010) (entrectinib)
11019361427140
8071427140

Protein Interaction Comparison

ProteinTaxonomyorantinib (IC50)entrectinib (IC50)
Aurora kinase AHomo sapiens (human)0.215
Tyrosine-protein kinase JAK2Homo sapiens (human)0.04
High affinity nerve growth factor receptorHomo sapiens (human)0.0059
Insulin receptorHomo sapiens (human)0.209
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.393
Insulin-like growth factor 1 receptorHomo sapiens (human)0.122
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)0.0072
Tyrosine-protein kinase JAK1Homo sapiens (human)0.112
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.164
Tyrosine-protein kinase JAK3Homo sapiens (human)0.349
Focal adhesion kinase 1Homo sapiens (human)0.14
Activated CDC42 kinase 1Homo sapiens (human)0.07
Protein-tyrosine kinase 6Homo sapiens (human)0.195
NT-3 growth factor receptorHomo sapiens (human)0.0049
BDNF/NT-3 growth factors receptorHomo sapiens (human)0.0037
Serine/threonine-protein kinase LMTK3Homo sapiens (human)4.653
Echinoderm microtubule-associated protein-like 4Homo sapiens (human)0.3307
ALK tyrosine kinase receptorHomo sapiens (human)0.1075

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1

Other Studies

2 other study(ies) available for orantinib and entrectinib

ArticleYear
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011